Study of clinical management and outcome of gastric cancer patients at a tertiary care hospital

2021 ◽  
Vol 19 (1) ◽  
pp. 22-26
Author(s):  
Anil Degaonkar ◽  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Distal Gastrectomy ◽  
Subtotal Gastrectomy ◽  
The Body ◽  
Statistical Association ◽  
Icu Stay ◽  
Gastric Cancer Patients ◽  
Study Participants ◽  
Significant Statistical Association

Background: Gastric Cancer is the second most common cancer worldwide surpassed only by lung cancer as the leading cause of cancer deaths. Early disease has minimal, non-specific or no symptoms. Therefore prognosis for gastric cancer patients remain poor as most patients are diagnosed in advanced stages. Present study was thus undertaken to study various etiological risk factors, clinical presentations and associated complications in cases of Carcinoma stomach. Material and Methods: Present study was a hospital based prospective observational study conducted in diagnosed cases of gastric carcinoma underwent surgery at our tertiary hospital. Results: In present study total 25 patients were studied. Majority of the study participants were in the age group of 61-65 years (40 %), and male (64%) were more than female (36%), male: female ratio was 1.8:1. There was no statistical association between TNM staging and outcome (p=0.4401). 36 % of the study subjects were found to have tumour in the body of stomach and underwent subtotal gastrectomy. Whereas 64 % of the participant had tumour in the pylorus and underwent distal gastrectomy and palliative gastro jejunostomy. There is no statistical association between type of surgery and outcome. 16% of the total study participants developed ARDS. The most common complication encountered was pneumonia in 20% of the subjects. 44 % did not develop any complications after surgery. Significant statistical association between complications and outcome (p=0.003). 100% of the participants who underwent distal gastrectomy had ICU stay less than 10 days, 45.45% of the participants who underwent palliative gastro jejunostomy and 44.44% of the subjects who underwent sub-total gastrectomy had ICU stay less than 10 days. Conclusion: 36% had tumor in the body of stomach and underwent subtotal gastrectomy, 64% had tumor in the pylorus and underwent distal gastrectomy and palliative gastro jejunostomy. Highly significant statistical association was noted between ICU stay/ complications and outcome of surgery.

scholarly journals The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0206930 ◽  
Author(s):  
Xi-Hsuan Lin ◽  
Kuo-Hung Huang ◽  
Wei-Hung Chuang ◽  
Jiing-Chyuan Luo ◽  
Chung-Chi Lin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Early Gastric Cancer ◽  
Cancer Patients ◽  
Metabolic Profile ◽  
Subtotal Gastrectomy ◽  
Term Effect ◽  
Long Term Effect ◽  
Gastric Cancer Patients

Docetaxel plus FOLFOX4 compared with FOLFOX4 as adjuvant chemotherapy for gastric cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 181-181
Author(s):  
Chun-Xia Du ◽  
Xiao-Yan Liu ◽  
Hong-Gang Zhang ◽  
Ai-Ping Zhou
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Survival Rates ◽  
Subtotal Gastrectomy ◽  
Disease Free Survival ◽  
Adjuvant Radiation ◽  
Ptnm Stage ◽  
Gastric Cancer Patients

181 Background: To compare the efficacy of docetaxel plus FOLFOX4 to FOLFOX4 as adjuvant chemotherapy for gastric cancer patients. Methods: 320 patients with stage IB-IV (M0) gastric cancer were enrolled into the retrospective study. All patients received a total or subtotal gastrectomy with at least D1 lymph nodes dissection. 193 patients received FOLFOX4 as adjuvant chemotherapy. 127 patients received biweekly docetaxel plus FOLFOX4 (DOF regimen) as adjuvant chemotherapy. Docetaxel was administered at 40 mg/m2 on day 1, followed by FOLFOX4 regimen. Both of the regimens were repeated every 2 weeks for a maximum of 12 cycles. Results: In comparison with patients in FOLFOX4 group, patients in DOF group were relatively younger (p=.001), with more advanced disease in pN stage (p=.035) and pTNM stage (p=.031), received more cycles of adjuvant chemotherapy (p=.004), and had a higher percentage of adjuvant radiation (p =.002). After adjustment of unbalanced variables as mentioned above, no statistical difference was observed between DOF group and FOLFOX4 group in terms of 3-year disease-free survival (54% vs 69%, p = 0.100, HR 1.362, 95% CI (0.943-1.967)) and 3-year overall survival(70% vs 72%, p = 0.810, HR 1.049, 95% CI (0.711-1.548)). Stratified analysis according to clinicopathologic characters showed that there were almost no statistical differences of 3-year overall survival rates between two groups, except the primary site (middle 1/3) (p =.025) and pTNM stage (IIb stage) (p =.035) in favor of FOLFOX4 group. The incidences of grade 3/4 adverse events were obviously higher in DOF group than in FOLFOX4 group,including decreased appetite (18.1% V 10.4%, P = 0.046), diarrhea (4.7% V 0%, p=0.004 ), hypersensitivity reactions to oxaliplatin (3.1% V 0%, p=0.024) and neutropenia (47.3% V 31.6%, p=0.004). Conclusions: Compared to FOLFOX4 regimen, adjuvant docetaxel plus FOLFOX4 did not show significant survival advantages in gastric cancer patients. However, a more serious toxicity profile was observed in docetaxel plus FOLFOX4 arm. Further studies are needed to decide whether triplet regimen is appropriate as adjuvant chemotherapy of gastric cancer.

Prevalence of HER2/neu overexpression/amplification in a Hispanic population with gastric adenocarcinoma.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 25-25
Author(s):  
M. Rodarte Shade ◽  
J. Flores Gutierrez ◽  
L. Garcia Labastida ◽  
L. Villela ◽  
A. Barbosa Quintana ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Gastric Adenocarcinoma ◽  
The Body ◽  
Hispanic Population ◽  
Hispanic Patients ◽  
Cancer Tumor ◽  
Study Population ◽  
Gastric Cancer Patients ◽  
Degree Of Differentiation

25 Background: In Europe, Asia, and North America, studies have identified that approximately 20% of patients with gastric adenocarcinoma exhibit overexpression of HER2/neu. This group of patients has been shown to benefit from combination therapy with the anti-HER2/neu monoclonal antibody trastuzumab. These findings have not been studied in Hispanics who may possess a distinct gastric cancer genotype. The aim of this study is to determine the rate of HER2/neu positivity in a completely Hispanic population with gastric adenocarcinoma and to analyze the clinical factors associated with HER2/neu. Methods: We conducted a retrospective study in three different hospitals in Monterrey, Mexico. The study population consisted of Hispanic patients with gastric adenocarcinoma who have had a gastric resection and for whom there were adequate amounts of tissue available in paraffin blocks. Tissue was tested for HER2/neu using both Immunohistochemistry (IHC) and the fluorescent in situ hybridization (FISH) techniques. Results: From 2000 to 2010, we initially evaluated 27 gastric cancer tumor samples. Sex distribution was 15 males and 12 females with a mean age of 57±15 (SD) years. Anatomic distribution of tumor was 4% in the cardias, 40% in the body and 56% in the antrum. Lauren's histological type distribution was 52% diffuse and 48% intestinal. Fifty-three percent of the tumors were high grade and nodal positivity was present in 69%. Overexpression of Her-2/neu (IHC ++ and +++) was found in five (17.4%) of the samples, being moderate (++) in two (7.4%) and strong (+++) in three (11%) tumor samples. FISH amplification for the HER2/neu gene was found in two (7.4%) tumors and was only seen in samples with a strong (+++) IHC result. There was no association identified between HER2/neu status with age, gender, degree of differentiation, T stage, or nodal status. Conclusions: In a homogeneous Hispanic population, 17.4% of gastric cancer patients were found to overexpress HER2/neu by IHC. FISH did not identify any additional HER2/neu positive tumors. It is important to consider IHC testing for HER2/neu in Hispanic gastric cancer patients as they could benefit from a chemotherapy regimen containing trastuzumab. No significant financial relationships to disclose.

scholarly journals Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers

2012 ◽  
Vol 27 (6) ◽  
pp. 410-416 ◽  
Author(s):  
David Hoskovec ◽  
Jozef Varga ◽  
Ellen Konečná ◽  
František Antoš
Keyword(s):  
Gastric Cancer ◽  
Pancreatic Cancer ◽  
Pancreatic Carcinoma ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Peritoneal Cavity ◽  
Residual Disease ◽  
Biological Fluids ◽  
The Body ◽  
Gastric Cancer Patients

PURPOSE: Tumor markers are substances found in blood and other biological fluids if tumor is present in the body. They can be produced by tumor itself or can be results of cancer - body relation. They may be used in the follow-up of cancer patients to identify tumor recurrence. Pre-treatment levels have prognostic tool and could signalize persistence of minimal residual disease despite radical surgery. METHODS: We operated on 52 patients with upper GI malignancy (32 with gastric cancer and 20 with pancreatic cancer). Blood samples were taken before surgery and peritoneal samples immediately after laparotomy before any manipulation with tumor. All samples were examined by standard biochemical technique and the level was compared with a stage of the disease. RESULTS: Patients suffering from gastric carcinoma of stage I and II had higher level of both markers in sera then in the peritoneal cavity, however most of them were within physiological range. Patients in stage III and IV had average marker levels in the peritoneal cavity higher than in sera. Number of positive findings was increasing according to the stage of the disease. The peritoneal levels of both markers varied extremely in higher stages. In patients suffering from pancreatic carcinoma the CEA levels both in sera and peritoneal cavity were parallel but peritoneal levels were slightly higher in stages III and IV. Ca 19 - 9 was more sensitive for pancreatic cancer. The percentage of positive findings was higher in sera but the level of Ca 19 - 9 was higher in the peritoneal cavity. The number of positive findings again correlated with the stage of the disease. CONCLUSIONS: Levels of tumor markers in sera could signalize inoperability of tumor (Ca 19 - 9 in cases of pancreatic carcinoma); peritoneal levels could predict R1 resection especially in gastric cancer patients and risk of early peritoneal recurrence of the disease. Difference between the levels in the peritoneum and sera may signalize the route of dissemination (hematogenous and intraperitoneal).

scholarly journals Totally Robotic Distal Gastrectomy: A Safe and Feasible Minimally Invasive Technique for Gastric Cancer Patients Who Undergo Distal Gastrectomy

2020 ◽  
Vol 37 (5) ◽  
pp. 360-367
Author(s):  
Yong Kuang ◽  
Sanlin Lei ◽  
Hua Zhao ◽  
Beibei Cui ◽  
Kuijie Liu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Minimally Invasive ◽  
Cancer Patients ◽  
Distal Gastrectomy ◽  
Operating Time ◽  
Disease Free Survival ◽  
Invasive Technique ◽  
Estimated Blood Loss ◽  
Gastric Cancer Patients ◽  
Central South

Purposes: To explore the safety and feasibility of totally robotic distal gastrectomy (TRDG) for gastric cancer patients who undergo distal gastrectomy. Methods: Consecutive patients with gastric cancer who underwent TRDG (TRDG group) and robotic-assisted distal gastrectomy (RADG) (RADG group) were systematically reviewed at the Second Xiangya Hospital of Central South University from October 2015 to August 2018. Data were collected and statistically analyzed. Results: A total of 161 consecutive patients were included in this study: 84 cases in the TRDG group and 77 in the RADG group. Clinical characteristics and pathological results were mostly similar in both groups. The TRDG group had a significantly longer anastomotic time (20.6 ± 3.3 vs. 17.5 ± 4.0 min, p ˂ 0.001) but showed no difference in total operating time (167.0 ± 18.0 vs. 162.9 ± 17.6 min, p = 0.159). The postoperative hospitalization in the TRDG group was shorter than that in the RADG group (6.7 ± 1.2 vs. 7.2 ± 1.7 days, p = 0.019). Conversion rate, estimated blood loss, and postoperative complications were similar in both groups. There were no statistical differences in the estimated 2-year disease-free survival and overall survival rate between both groups. Conclusions: Although our current results need to be verified in further studies, TRDG represents a safe and feasible approach to distal gastrectomy and embodies the theory of minimally invasive surgery.

Sign in / Sign up

Export Citation Format

Share Document